

**BEFORE THE FEDERAL TRADE COMMISSION  
UNITED STATES OF AMERICA**

---

<b>IN THE MATTER OF</b>	)	
	)	
<b>SUN PHARMACEUTICAL INDUSTRIES LTD.,</b>	)	
<b>a corporation;</b>	)	
	)	
<b>RANBAXY LABORATORIES LTD.,</b>	)	<b>FTC File No. 141-0134</b>
<b>a corporation;</b>	)	
	)	
<b>and</b>	)	
	)	
<b>DAIICHI SANKYO CO., LTD.</b>	)	
<b>a corporation.</b>	)	

---

**AGREEMENT CONTAINING CONSENT ORDERS**

The Federal Trade Commission (“Commission”), having initiated an investigation of the proposed acquisition by Proposed Respondent Sun Pharmaceutical Industries Ltd. (“Sun”) of the voting securities of Proposed Respondent Ranbaxy Laboratories Ltd. (“Ranbaxy”), a subsidiary of Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”), hereinafter “Proposed Respondents,” and it now appearing that Proposed Respondents are willing to enter into this Agreement Containing Consent Orders (“Consent Agreement”) to divest certain assets and providing for other relief:

**IT IS HEREBY AGREED** by and between Proposed Respondents, by their duly authorized officers and attorneys, and counsel for the Commission that:

1. Proposed Respondent Sun is a corporation organized, existing, and doing business under and by virtue of the laws of the Republic of India, with its headquarters located at Acme Plaza, Andheri Kurla Road, East Andheri, Mumbai 400 059, India. The headquarters for Sun’s U.S. subsidiary, Sun Pharmaceutical Industries, Inc., is located at 270 Prospect Plains Road, Cranbury, New Jersey, 08512, USA.
  
2. Proposed Respondent Ranbaxy is a corporation organized, existing, and doing business under and by virtue of the laws of the Republic of India with its headquarters located at Plot No. 90, Sector 32, Gurgaon-122001 (Haryana), India. The headquarters for Ranbaxy’s U.S. subsidiary, Ranbaxy Inc., is located at 600 College Road East, Suite 2100, Princeton, New Jersey, 08540, USA.

AGREEMENT CONTAINING CONSENT ORDERS

*In the Matter of Sun Pharmaceutical Industries Ltd., et al.*

FTC File No. 141-0134

3. Proposed Respondent Daiichi Sankyo is a corporation organized, existing, and doing business under and by virtue of the laws of Japan with its headquarters located at 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan. The headquarters for Daiichi Sankyo's U.S. subsidiary, Daiichi Sankyo, Inc., is located at Two Hilton Court, Parsippany, New Jersey, 07054, USA.
4. Each Proposed Respondent admits all the jurisdictional facts set forth in the draft of Complaint here attached.
5. Each Proposed Respondent waives:
  - a. any further procedural steps;
  - b. the requirement that the Commission's Decision and Order and Order to Maintain Assets, both of which are attached hereto and made a part hereof, contain a statement of findings of fact and conclusions of law;
  - c. all rights to seek judicial review or otherwise challenge or contest the validity of the Decision and Order or the Order to Maintain Assets entered pursuant to this Consent Agreement; and
  - d. any claim under the Equal Access to Justice Act.
6. Because there may be interim competitive harm, the Commission may issue its Complaint and the Order to Maintain Assets in this matter at any time after it accepts this Consent Agreement for public comment.
7. Not later than thirty (30) days after the date this Consent Agreement is signed by the Proposed Respondents, each Proposed Respondent shall submit an initial report, pursuant to Section 2.33 of the Commission's Rules, 16 C.F.R. § 2.33. Each Proposed Respondent shall also submit subsequent reports every thirty (30) days thereafter until the Order to Maintain Assets becomes final, at which time the reporting obligations contained in the Order to Maintain Assets (other than the requirement to submit an initial report pursuant to this Consent Agreement) shall control. Such reports shall be signed by the respective Proposed Respondent and shall set forth in detail the manner in which that Proposed Respondent has complied and will comply with the Order to Maintain Assets and the Decision and Order. Such reports will not become part of the public record unless and until the Consent Agreement and Decision and Order are accepted by the Commission for public comment.
8. In each report described in Paragraph 7, each Proposed Respondent shall provide sufficient information and documentation to enable the Commission to determine independently whether that Proposed Respondent is in compliance with this Consent Agreement and each of the Orders. Each report shall be verified by a notarized signature or sworn statement of an employee of the relevant Proposed Respondent specifically authorized to perform this function, or shall be self-verified in the manner set forth in 28

## AGREEMENT CONTAINING CONSENT ORDERS

*In the Matter of Sun Pharmaceutical Industries Ltd., et al.*

FTC File No. 141-0134

U.S.C. § 1746. Section 2.41(a) of the Commission's Rules of Practice requires that an original and two (2) copies of all compliance reports be filed with the Commission. Each Proposed Respondent shall file an original report and one (1) copy with the Secretary of the Commission, and shall send at least one (1) copy directly to the Bureau of Competition's Compliance Division.

9. This Consent Agreement shall not become part of the public record of the proceeding unless and until it is accepted by the Commission. If this Consent Agreement is accepted by the Commission, it, together with the draft of Complaint contemplated thereby, will be placed on the public record for a period of thirty (30) days and information in respect thereto publicly released. The Commission thereafter may either withdraw its acceptance of this Consent Agreement and so notify Proposed Respondents, in which event it will take such action as it may consider appropriate, or issue or amend its Complaint (in such form as the circumstances may require) and issue its Decision and Order, in disposition of the proceeding.
10. This Consent Agreement is for settlement purposes only and does not constitute an admission by Proposed Respondents that the law has been violated as alleged in the draft of Complaint here attached, or that the facts as alleged in the draft of Complaint, other than jurisdictional facts, are true.
11. This Consent Agreement contemplates that, if it is accepted by the Commission, the Commission may (i) issue and serve its Complaint corresponding in form and substance with the draft of Complaint here attached, (ii) issue and serve its Order to Maintain Assets, and (iii) make information public with respect thereto. If such acceptance is not subsequently withdrawn by the Commission pursuant to the provisions of Commission Rule 2.34, 16 C.F.R. § 2.34, the Commission may, without further notice to Proposed Respondents, issue the attached Decision and Order containing an order to divest and providing for other relief in disposition of the proceeding.
12. When final and effective, the Decision and Order and the Order to Maintain Assets shall have the same force and effect and may be altered, modified or set aside in the same manner and within the same time provided by statute for other orders. The Decision and Order and the Order to Maintain Assets shall become final and effective upon service. Delivery of the Complaint, the Decision and Order, and the Order to Maintain Assets to Proposed Respondent Sun by any means provided in Commission Rule 4.4(a), 16 C.F.R. § 4.4(a) – including, but not limited to, delivery to an office within the United States of Jessica K. Delbaum, Esq., of Shearman & Sterling LLP; or of any other lawyer or law firm listed as Counsel for Sun – shall constitute service as to Proposed Respondent Sun. Delivery of the Complaint, the Decision and Order, and the Order to Maintain Assets to Proposed Respondent Ranbaxy by any means provided in Commission Rule 4.4(a), 16 C.F.R. § 4.4(a) – including, but not limited to, delivery to an office within the United States of Stacey Anne Mahoney, Esq., of Morgan, Lewis & Bockius LLP; or of any other lawyer or law firm listed as Counsel for Ranbaxy – shall constitute service as to Proposed Respondents Ranbaxy. Delivery of the Complaint, the Decision and Order, and the Order to Maintain Assets to Proposed Respondent Daiichi Sankyo by any means provided in

- Commission Rule 4.4(a), 16 C.F.R. § 4.4(a) – including, but not limited to, delivery to an office within the United States of Ronan P. Harty, Esq., of Davis Polk & Wardwell LLP; or of any other lawyer or law firm listed as Counsel for Daiichi Sankyo – shall constitute service as to Proposed Respondents Daiichi Sankyo. Each Proposed Respondent waives any right it may have to any other manner of service. Each Proposed Respondent also waives any right it may otherwise have to service of any Appendices incorporated by reference into the Decision and Order, and agrees that it is bound to comply with and will comply with the Decision and Order to the same extent as if it had been served with copies of the Appendices, where Proposed Respondent is already in possession of copies of such Appendices.
13. The Complaint may be used in construing the terms of the Decision and Order and the Order to Maintain Assets, and no agreement, understanding, representation, or interpretation not contained in the Decision and Order, the Order to Maintain Assets, or the Consent Agreement may be used to limit or contradict the terms of the Decision and Order or the Order to Maintain Assets.
  14. By signing this Consent Agreement, Proposed Respondents represent and warrant that Proposed Respondents can accomplish the full relief contemplated by the attached Decision and Order (including effectuating all required divestitures, assignments, and transfers) and the Order to Maintain Assets, and that all parents, subsidiaries, affiliates, and successors necessary to effectuate the full relief contemplated by this Consent Agreement are: (i) within the control of the parties to this Consent Agreement, or (ii) will be in the control of the parties to this Consent Agreement after the proposed acquisition.
  15. By signing this Consent Agreement, Proposed Respondents represent and warrant that each Remedial Agreement (as defined in the Decision and Order) that has been submitted to the Commission at the time of this Consent Agreement for approval by the Commission in connection with the Commission's determination to make the Decision and Order final comports with all of the relevant requirements of the Decision and Order and requires Proposed Respondents to divest all assets required to be divested pursuant to the relevant requirements of the Decision and Order.
  16. Each Proposed Respondent agrees that it shall interpret each Remedial Agreement in a manner that is fully consistent with all of the relevant provisions and remedial purposes of the Decision and Order.
  17. Each Proposed Respondent has read the draft of Complaint, the Decision and Order, and the Order to Maintain Assets contemplated hereby. Each Proposed Respondent understands that once the Decision and Order and the Order to Maintain Assets have been issued, it will be required to file one or more compliance reports showing that it has fully complied with the Decision and Order and the Order to Maintain Assets.
  18. Each Proposed Respondent agrees to comply with the terms of the proposed Decision and Order and the Order to Maintain Assets from the date it signs this Consent Agreement.

AGREEMENT CONTAINING CONSENT ORDERS

*In the Matter of Sun Pharmaceutical Industries Ltd., et al.*

FTC File No. 141-0134

Each Proposed Respondent further understands that it may be liable for civil penalties in the amount provided by law for each violation of the Decision and Order and of the Order to Maintain Assets after they become final and effective.

**SUN PHARMACEUTICAL INDUSTRIES LTD.**

By: \_\_\_\_\_  
Dilip S. Shanghvi  
Managing Director  
Sun Pharmaceutical Industries Ltd.

Date: \_\_\_\_\_

\_\_\_\_\_  
Jessica K. Delbaum, Esq.  
Shearman & Sterling LLP  
Counsel for Sun Pharmaceutical Industries Ltd.

AGREEMENT CONTAINING CONSENT ORDERS  
*In the Matter of Sun Pharmaceutical Industries Ltd., et al.*  
FTC File No. 141-0134

**RANBAXY LABORATORIES LTD.**

By: \_\_\_\_\_  
Arun Sawhney  
Chief Executive Officer & Managing Director

Ranbaxy Laboratories Ltd.

Date: \_\_\_\_\_

\_\_\_\_\_  
Stacey Anne Mahoney, Esq.  
Morgan, Lewis & Bockius LLP  
Counsel for Ranbaxy Laboratories Ltd.

AGREEMENT CONTAINING CONSENT ORDERS  
*In the Matter of Sun Pharmaceutical Industries Ltd., et al.*  
FTC File No. 141-0134

**DAIICHI SANKYO CO., LTD.**

By: \_\_\_\_\_

Joji Nakayama  
President & Chief Executive Officer

Daiichi Sankyo Co., Ltd.

Date: \_\_\_\_\_

\_\_\_\_\_  
Ronan P. Harty, Esq.  
Davis Polk & Wardwell LLP  
Counsel for Daiichi Sankyo Co., Ltd.



AGREEMENT CONTAINING CONSENT ORDERS  
*In the Matter of Sun Pharmaceutical Industries Ltd., et al.*  
FTC File No. 141-0134

**FEDERAL TRADE COMMISSION**

By: \_\_\_\_\_  
Daniel K. Zach  
Deputy Assistant Director  
Bureau of Competition

\_\_\_\_\_  
Michael R. Moiseyev  
Assistant Director  
Bureau of Competition

\_\_\_\_\_  
Stephen Weissman  
Deputy Director  
Bureau of Competition

\_\_\_\_\_  
Deborah L. Feinstein  
Director  
Bureau of Competition  
Date: \_\_\_\_\_